FDA Approves KYGEVVI®, the First and Only Treatment for Thymidine Kinase 2 deficiency (TK2d)

Care and Connection That Matter

Access to care, trusted guidance, and meaningful programs that support individuals and families—every step of the way.

Conversations About RADICAVA ORS® (edaravone) Chapter 3: An ALS Caregiver's Perspective

Tuesday, August 15, 2023
11:00 AM - 11:30 AM CT
30 minutes

In this Industry Update Webinar for the community presented by Mitsubishi Tanabe Pharma America (MTPA), Gia, an ALS caregiver and advocate, provides a caregiver’s perspective of MTPA’s RADICAVA ORS® (edaravone) that provides patients with ALS a flexible treatment administration option.

Register

If you have questions or comments, contact cdrummond@mdausa.org . For more educational programs and resources, please visit mda.org/community-ed.

This Industry Update Webinar is sponsored by MTPA. MDA is providing this resource as an educational opportunity for the neuromuscular disease community. This program is not sponsored, endorsed, or accredited by MDA.

Mitsubishi Tanabe Pharma, America